Press "Enter" to skip to content
Gilead Sciences to Present Gilead-Kite Oncology portfolio

Gilead Sciences to Present Gilead-Kite Oncology portfolio

By Willie Wise on May 24, 2021

Gilead Sciences Inc shares advanced 1.24% to $69.35 Thursday. This proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.06% to 4,159.12 and the Dow Jones Industrial Average DJIA rising 0.55% to 34,084.15. The stock’s rise snapped a two-day losing streak.

Gilead Sciences Inc. closed $9.96 below its 52-week high ($79.31), which the company achieved on June 8th. The stock outperformed some of its competitors Thursday, as Johnson & Johnson JNJ rose 0.58% to $171.07, Merck & Co. Inc. MRK rose 0.38% to $79.66, and AbbVie Inc. ABBV rose 1.09% to $117.11. Trading volume (6.5 M) remained 762,501 below its 50-day average volume of 7.3 M.

Gilead Sciences, Inc.and Kite, a Gilead Company, that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate, as well as Kite’s chimeric antigen receptor T-cell therapies across a range of cancers, including in existing indications and for investigational uses.

Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences Inc said that Gilead-Kite Oncology is quickly advancing transformative science for people facing historically difficult-to-treat cancers. The first-in-class, TROP-2 directed ADC therapy is having an impact on people with metastatic triple-negative breast and urothelial cancers. The data at ASCO will add insight into its utility in TNBC in both monotherapy and future combination treatment approaches.

Published in Biotechnology and News

Willie Wise

Backed by a strong educational background with a degree in Biotechnology, Greenville Technical College, Willie D. Wise is an asset to The Healthcare News and is rightfully placed as the Chief Editor, owing to his vast experience in technical writing, marketing, and strategic planning. To hone his job skills in journalism, Wise has also completed a degree course in journalism from the University of South Carolina-Columbia. He is highly skilled with the art of news presentation and is adept in an editorial role with excellent time management and leadership qualities at his disposal. He ensures the best delivery from his team of writers and ensures excellent performance by his team. Besides his current job as the editor-in-chief at The Healthcare News, he is a regular writer for the biotechnology category. Given his intense interest in the field, his core career centers around writing which he does with complete dexterity. As a writer, he ensures appropriate title selection besides developing authentic, market-relevant content ideal for business discretion and also to suit promotional and marketing strategies of TheHealthcareNews. His writing style not only remains informative but also is high on lucidity to entice reader focus for longer. Crude facts and statistical details are also presented simplistically to connect with readers' grasping capabilities.

More from BiotechnologyMore posts in Biotechnology »
More from NewsMore posts in News »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *